Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.45 -1.67 (-2.35%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
67 68 Next >
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE- 
Via Benzinga
AstraZeneca advances scientific leadership in hematology at ASH 2023
From AstraZeneca
Via Business Wire
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
Via Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront... 
Via Talk Markets
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
Could AstraZeneca be an under-rated buy right now? 
Via The Motley Fool
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
Price Over Earnings Overview: AstraZeneca
Via Benzinga
3 No-Brainer Stocks to Buy With $1,000 Right Now
A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts. 
Via The Motley Fool
5 Growth Stocks to Buy for 2024
Forget the "Magnificent 7." These are the top five growth stocks to buy in the coming year for interested investors. 
Via InvestorPlace
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
From AstraZeneca
Via Business Wire
3 stocks that crushed earnings estimates and still tanked
Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks 
Via MarketBeat
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
The U.S. 
Via Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
It might have a hard time finding a home in the market. 
Via The Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks. 
Via InvestorPlace
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential. 
Via InvestorPlace
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
AZN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%. 
Via Talk Markets
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly. 
Via Investor's Business Daily
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u 
Via Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. 
Via Benzinga
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth
AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023. 
Via Talk Markets
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
From AstraZeneca
Via Business Wire
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.